2018 Competitor Analysis: WT1-Targeted Immunotherapy - ResearchAndMarkets.com

June 13, 2018

DUBLIN--(BUSINESS WIRE)--Jun 13, 2018--The “Competitor Analysis: WT1-Targeted Immunotherapy” report has been added to ResearchAndMarkets.com’s offering.

This Competitive Intelligence report analyzes the competitive field of WT1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies targeting Wilms Tumor 1 (WT1). In addition, the report lists company- and institution-specific R&D pipelines of WT1-Targeted Immunotherapies.

Wilms tumor 1 (WT1) oncoprotein is a zinc finger transcription factor whose expression in normal adult tissue is rare but is overexpressed in leukemias of multiple lineages and a wide range of solid tumors. WT1 expression is a biomarker and a prognostic indicator.

RNA interference knockdown studies of WT1 suggest that it has oncogenic potential and it appears to be expressed in leukemia stem cell populations. A National Institutes of Health-convened panel ranked WT1 as a top cancer target for immunotherapy.

WT1 is a nuclear protein, inaccessible to classical antibody therapy, but vaccine approaches are under way to generate WT1-specific cytotoxic T cell (CTL) responses that recognize peptides presented on the cell surface by MHC class I molecules. Engineering autologous T-cells with a WT1-specific T-cell receptor (TCR) is another approach currently pursued.

Competitor projects are listed in a tabular format providing information on:

Drug Codes Target/Mechanism of Action Class of Compound Company Product Category Indication R&D Stage Additional comments with a hyperlink leading to the source of information

Key Topics Covered

1. WT1-Targeted Immunotherapy

Selective WT1-Targeted Vaccines WT1-Specific, Multi-Target Vaccines WT1-Selective Adoptive Cell Therapy WT1-Specific, Multi-Target Adoptive Cell Therapy WT1-Targeted Antibodies

2. Corporate & Institutional WT1 Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/fh877t/2018_competitor?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180613006268/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/13/2018 05:49 PM/DISC: 06/13/2018 05:49 PM


Update hourly